Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization

OncoImmunology

Volumn 3, Issue 10, 2014, Pages e958937-1-e958937-4

  Ranki, Tuuli ^a   Joensuu, Timo ^b   Jäger, Elke ^c   Karbach, Julia ^c   Wahle, Claudia ^c   Kairemo, Kalevi ^b   Alanko, Tuomo ^b   Partanen, Kaarina ^b   Turkki, Riku ^d   Linder, Nina ^d   Lundin, Johan ^d   Ristimäki, Ari ^d,e   Kankainen, Matti ^d   Hemminki, Akseli ^f   Backman, Charlotta ^a   Dienel, Kasper ^a   von Euler, Mikael ^a   Haavisto, Elina ^a   Hakonen, Tiina ^a   Juhila, Juuso ^a   Jaderberg, Magnus ^a   Priha, Petri ^a   Vassilev, Lotta ^a   Vuolanto, Antti ^a   Pesonen, Sari ^a   more..

^a Oncos Therapeutics Inc   (Finland)

^b International Comprehensive Cancer Center Docrates   (Finland)

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adenovirus; antitumor immunity; cytotoxic immunotherapy; GM CSF; Th1 polarization; tumor infiltrating lymphocytes

Indexed keywords

CD8 ANTIGEN; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULYSIN; GRANZYME B; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOLYTIC ADENOVIRUS; PERFORIN; RANTES; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADENOVIRIDAE; AGED; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; FOLLOW UP; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION; LOCAL THERAPY; LYMPHOCYTIC INFILTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLEURA MESOTHELIOMA; POLARIZATION; POSITRON EMISSION TOMOGRAPHY; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRUS PARTICLE;

EID: 84938634118     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.958937     Document Type: Article

References (24)

1. M.Obeid, A.Tesniere, F.Ghiringhelli, G.M.Fimia, L.Apetoh, J.L.Perfettini, M.Castedo, G.Mignot, T.Panaretakis, N.Casares Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
2. M.Paroli, F.Bellati, M.Videtta, C.Focaccetti, C.Mancone, T.Donato, M.Antonilli, G.Perniola, D.Accapezzato, C.Napoletano Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer 2013; 134:1823-34; PMID:24150888; http://dx.doi.org/10.1002/ijc.28515
3. S.Workenhe, K.L.Mossman. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunol 2013; 2:e27138; PMID:24498567; http://dx.doi.org/10.4161/onci.27138
4. D.Y.Sze, T.R.Reid, S.C.Rose. Oncolytic virotherapy. J Vasc Interv Radiol 2013; 24:1115-22; PMID:23885911; http://dx.doi.org/10.1016/j.jvir.2013.05.040
5. L.Spel, J.-J.Boelens, S.Nierkens, M.Boes. Antitumor immune responses mediated by dendritic cells. How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunol 2013; 2: e26403; PMID:24482744; http://dx.doi.org/10.4161/onci.26403
6. A.Koski, L.Kangasniemi, S.Escutenaire, S.Pesonen, V.Cerulleo, I.Diaconu, P.Nokisalmi, M.Raki, M.Rajecki, K.Guse Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/10.1038/mt.2010.161
7. G.Dranoff. GM-CSF based cancer vaccines. Immunol Rev 2002; 188:147-54; PMID:12445288; http://dx.doi.org/10.1034/j.1600-065X.2002.18813.x
8. L.van der Laar, P.J.Coffer, A.M.Woltman. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
9. V.Neumann, S.Leke, D.Nowak, F.J.F.Herth, A.Tannapfel. Malignant pleural mesothelioma. Dtsch Arztebl Int 2013; 110:319-26; PMID:23720698; http://dx.doi.org/10.3238/arztebl.2013.0319
10. P.Astoul, E.Roca, F.Galateau-Salle, A.Scherpereel. Malignant pleural mesothelioma: from the bench to the bedside. Respiration 2012; 83:481-93; PMID:22710421; http://dx.doi.org/10.1159/000339259
11. J.W.Shiver, T.-M.Fu, L.Chen, D.R.Casimiro, M.-E.Davies, R.K.Evans, Z.-Q.Zhang, A.J.Simon, W.L.Trigona, S.A.Dubey Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5; PMID:11797011; http://dx.doi.org/10.1038/415331a
12. B.Melichar, H.Studentova, H.Kalabova, D.Vitaskova, P.Cermakova, H.Hornychova, A.Ryska. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer res 2014; 34:1115-26; PMID:24596349
13. + tumor infiltrating lymphocytes predict favourable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010; 59:1543-49; PMID:20567822; http://dx.doi.org/10.1007/s00262-010-0881-6
14. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer res 2007; 67:354-61; PMID:17210718; http://dx.doi.org/10.1158/0008-5472.CAN-06-3388
15. + T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113:1387-95; PMID:18671239; http://dx.doi.org/10.1002/cncr.23712
16. F.Pages, A.Kirilovsky, B.Mlecnik, M.Asslaber, M.Tosolini, G.Bindea, C.Lagorce, P.Wind, F.Marliot, P.Bruneval In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
17. P.Balermpas, Y.Michel, J.Wagenblast, O.Seitz, C.Weiss, F.Rödel, C.Rödel, E.Fokas. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Brit J Cancer 2014; 110:501-9; PMID:24129245; http://dx.doi.org/10.1038/bjc.2013.640
18. B.W.Bridle, S.Hanson, B.D.Lichty. Combining oncolytic virotherapy and tumor vaccination. Cytokine Growth Factor Rev 2010; 21:143-48; PMID:20226716; http://dx.doi.org/10.1016/j.cytogfr.2010.02.009
19. + T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004; 64:2865-73; PMID:15087405; http://dx.doi.org/10.1158/0008-5472.CAN-03-3066
20. A.Schietinger, P.D.Greenberg. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014; 35:51-60; PMID:24210163; http://dx.doi.org/10.1016/j.it.2013.10.001
21. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
22. J.Galon, F.Pages, F.M.Marincola, M.Thurin, G.Trinchieri, B.A.Fox, T.Gajewski, P.A.Ascierto. The immune score as a new possible approach for the classification of cancer. J Translat Med 2012; 10:1-4; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1
23. + T-cell memory. Nat Rev 2008; 8:107-19; PMID:18219309; doi: 10.1038/nri2251
24. R.-R.Ji, S.D.Chasalow, L.Wang, O.Hamid, H.Schmidt, J.Cogswell, S.Alaparthy, D.Berman, M.Jure-Kunkel, N.O.Siemers An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61:1019-31; PMID:22146893; http://dx.doi.org/10.1007/s00262-011-1172-6